On September 3, 2019 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, U.S., and throughout the world, reported it will present at the 2019 H.C. Wainwright 21st Annual Global Investment Conference being held September 8-10, 2019 in New York, NY (Press release, CASI Pharmaceuticals, SEP 3, 2019, https://www.prnewswire.com/news-releases/casi-pharmaceuticals-inc-to-present-at-the-2019-hc-wainwright-21st-annual-global-investment-conference-300909977.html [SID1234539224]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 21st Annual Global Investment Conference
Date: Monday, September 9th
Time: 11:40 AM – 12:05 PM
Presenter: Dr. Wei-Wu He
Presentation Room: Holmes II (4th floor) Lotte New York Palace Hotel

A link to the presentation’s webcast as well as a copy of the of the presentation can found on the Company’s website www.casipharmaceuticals.com, on September 9, 2019.

On September 3, 2019 ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC (Press release, ProMIS Neurosciences, SEP 3, 2019, https://www.prnewswire.com/news-releases/promis-neurosciences-to-present-at-hc-wainwright-investment-conference-300909802.html [SID1234539223]). The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link View Source

On September 3, 2019 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will present at the following investor conferences (Press release, Insmed, SEP 3, 2019, View Source [SID1234539222]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright 21st Annual Global Investment Conference in New York, NY on Tuesday, September 10, 2019 at 8:20 a.m. ET.
The Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY on Tuesday, September 10, 2019 at 5:15 p.m. ET.
The presentations will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

On September 3, 2019 Luminex Corporation (NASDAQ: LMNX) reported that Homi Shamir, President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference to be held September 9-11, 2019, in New York, NY (Press release, Luminex, SEP 3, 2019, View Source [SID1234539221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will begin at 2:05 p.m. Eastern Time on Tuesday, September 10, 2019.

The presentation will be webcast live and may be accessed at Luminex Corporation’s website at www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. The presentation will be archived for six months on the website using the ‘replay’ link.

On September 3, 2019 SCL Health reported continues to build on its commitment to person-centered care and transforming the patient experience through innovative and cutting-edge cancer care (Press release, Strata Oncology, SEP 3, 2019, View Source [SID1234539220]). Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems. By partnering with the Strata Precision Oncology Network (the Network), SCL Health will be able to provide the benefits of the latest technology and clinical research in precision oncology to patients across Colorado and Montana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the Network, SCL Health patients will benefit from Strata’s precision oncology platform and comprehensive treatment program for personalized cancer care. Eligible cancer patients will have access to routine tumor molecular profiling, rapid interpretation of test results and the ability to participate in local precision therapy clinical trials.

"As our understanding of cancer becomes more complex, the advent of targeted therapies and immune-based therapies allow us to look at the genes that drive cancer. This has led to a whole new class of medications that enable us to treat cancer in a more precise way with potentially fewer side effects," said Alan Miller, MD, Chief Medical Director of Oncology and Associate Chief Medical Director of Clinical Research for SCL Health. "In order to leverage these new treatments, we need to characterize the cancer right down to its genetic roots. As part of the Network, we are able to offer this characterization at no cost to the patient and the results will ultimately inform a more precise treatment plan."

SCL Health is dedicated to empowering cancer patients through providing access to proven therapies and the latest scientifically-proven outcomes. SCL Health is one of two health systems in Colorado and the only health system in Montana to be part of the Strata Precision Oncology Network. This partnership will transform how patients find and access cutting-edge, quality cancer care in the Colorado-Montana region.

Media Contact:
Britta Robinson
Communications Director
303-813-5242
[email protected]